Drug Search Results
Using advanced filters...
Advanced Search [+]

Zosurabalpin

Alternative Names: Zosurabalpin, ro-7223280, ro 7223280, ro7223280, RG006
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zosurabalpin

Countries in Clinic: France, Israel, Korea, Moldova, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Communicable Diseases|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BP43949

P1

Completed

Communicable Diseases

2024-01-13

21%

BP41732

P1

Completed

Healthy Volunteers

2023-03-09

28%

Recent News Events